Anti-Interferon-alpha (Anti-IFN-alpha) ELISA KIT

Name: Anti-Interferon-alpha (Anti-IFN-alpha) ELISA KIT
SKU: DEIA6164
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, tissue homogenates and other biological fluids

Species Reactivity

Human

Detection Method

iELISA

Intended Use

For quantitative detection of IFN-α-Ab in serum, plasma, tissue homogenates and other biological fluids.

Contents of Kit

1. ELISA Microplate(Dismountable), 8×12, 2-8°C/-20°C
2. Lyophilized Standard, 2vial, 2-8°C/-20°C
3. Sample Dilution Buffer, 20ml, 2-8°C
4. HRP-labeled Antibody(Concentrated), 120ul, 2-8°C(Avoid Direct Light)
5. Antibody Dilution Buffer, 10ml, 2-8°C
6. TMB Substrate, 10ml, 2-8°C(Avoid Direct Light)
7. Stop Solution, 10ml, 2-8°C
8. Wash Buffer(25×), 30ml, 2-8°C
9. Plate Sealer, 5pieces
10. Product Description, 1copy

Storage

2-8°C

Performance Characteristics

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% within the expiration date under appropriate storage condition.

To minimize extra influence on performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is strongly suggested that the same operator performs the whole assay from the beginning to the end.

Precision

Intra-Assay: CV<8%
Inter-Assay: CV<10%

Detection Range

1.563-100ng/ml

Sensitivity

0.938ng/ml

Standard Curve

Results of a typical standard operation of a IFN-α-Ab ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)

Citations

Have you cited DEIA6164 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus

TISSUE ANTIGENS

Authors: Hirankarn, N.; Tangwattanachuleeporn, M.; Wongpiyabovorn, J.; Wongchinsri, J.; Avihingsanon, Y.

Abstract

In this study, the association between the systemic lupus erythematosus (SLE) susceptibility and the new candidate genes, IFNA1, IFNA2 and IFNA5 genes, major interferon-alpha subtypes, in responses to viral infection was investigated. Allele and genotype frequencies of each marker were compared between 150 SLE patients and 150 healthy control subjects. This study indicated that the A/A genotype of IFNA5 (-2529) and the G/G genotype of IFNA1 (-1823) were associated with the protection of SLE disease in a recessive model [P-c = 0.03, P = 0.01, odds ratio (OR) = 0.4, 95% confidence interval (CI) = 0.2-0.8 and P-c = 0.09, P = 0.03, OR = 0.5, 95% CI = 0.2-0.9, respectively). Multifactor dimensionality reduction analysis showed a marginal interaction between IFNA5 (-2529) and IFNA1 (-1823) gene, with a cross-validation consistency of 10 of 10 and a prediction error of 46% (permutation P-value = 0.05). This is the first report of positive association of IFNA gene in SLE, especially the role of specific subtypes IFNA1 and IFNA5.

Relationship between IFNA1, IFNA5, IFNA10, and IFNA17 gene polymorphisms and Crimean-Congo hemorrhagic fever prognosis in a Turkish population range

JOURNAL OF MEDICAL VIROLOGY

Authors: Elaldi, Nazif; Yilmaz, Meral; Bagci, Binnur; Yelkovan, Izzet; Bagci, Gokhan; Gozel, Mustafa Gokhan; Engin, Aynur; Bakir, Mehmet; Dokmetas, Ilyas

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a fatal emerging acute viral infection. Not much is known regarding the pathogenic mechanisms and the reasons behind severe or mild disease courses in CCHF. IFN-alpha (IFNA) is one of the essential cytokines in the immune system. Existence of single nucleotide gene polymorphisms (SNPs) in cytokines can cause susceptibility or resistance to viral agents and different clinical courses. Hence, the relationship between SNPs in genes encoding cytokines (IFNA1 -1823G/A (rs1332190), IFNA5 -2529T/A (rs758236), IFNA10 Cys20stop (rs10119910), and IFNA17 Ile184Arg (rs9298814) SNPs and disease susceptibility were investigated. The associations between SNPs and CCHF prognosis were also studied. Total 150 patients with CCHF and 170 healthy individuals were enrolled. Genotyping was performed by PCR-RFLP methods. The frequency of IFNA1 -1823 (rs1332190) GG genotype was significantly higher in control subjects than CCHF patients (20% vs. 8%; P=0.01). For IFNA17 Ile184Arg (rs9298814) polymorphism, CCHF patients having TG genotype had a higher frequency than the control subjects (38% vs. 32.4%; P=0.039). The distribution of TT+TG genotype frequencies was also significantly higher in CCHF group than the controls (97.3% vs. 91.8%; P=0.049). Genotype and allele frequencies for IFNA subtypes between fatal and survivors were the same (P>0.05). Genotype and allele frequencies between severe and mild/moderate CCHF patients were also the same (P>0.05). The results show that IFNA1 rs1332190 and IFNA17 rs9298814 SNPs may play an important role in CCHF susceptibility. Determining the existence of other connections for IFNA SNPs and CCHF severity and fatality requires further investigations. J. Med. Virol. 88:1159-1167, 2016. (c) 2015 Wiley Periodicals, Inc.